Combined treatment with a USP8 inhibitor and anti-PD-L1 therapy markedly inhibits pancreatic tumor growth, mediated through activation of cytotoxic T cells and the PD-L1/CD8+ T-cell axis. This evidence concerns the gene USP8 and pancreatic neoplasm.